261780 — CHA Vaccine Research Institute Income Statement
0.000.00%
Last trade - 00:00- KR₩130bn
- KR₩95bn
- KR₩294m
Annual income statement for CHA Vaccine Research Institute, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 126 | 77.8 | 500 | 179 | 294 |
| Cost of Revenue | |||||
| Gross Profit | 86.1 | 64.8 | 500 | 160 | 260 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Total Operating Expenses | 3,000 | 4,312 | 6,585 | 6,649 | 6,713 |
| Operating Profit | -2,874 | -4,234 | -6,085 | -6,469 | -6,419 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2,980 | -6,240 | -18,420 | -6,715 | -2,103 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2,980 | -6,240 | -18,420 | -6,715 | -1,749 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2,980 | -6,240 | -18,420 | -6,715 | -1,749 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2,980 | -6,240 | -18,420 | -6,715 | -1,749 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -113 | -236 | -790 | -254 | -65.7 |
| Dividends per Share |